Vasovist-enhanced MR angiography
Vasovist (MS-325) is the first intravascular contrast agent approved for use with magnetic resonance angiography in the European Union. Vasovist reversibly binds to albumin, providing extended intravascular enhancement compared to existing extracellular magnetic resonance contrast agents. Prior to a...
Gespeichert in:
| Veröffentlicht in: | European radiology 2006-02, Vol.16 Suppl 2 (S2), p.B9-B14 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | B14 |
|---|---|
| container_issue | S2 |
| container_start_page | B9 |
| container_title | European radiology |
| container_volume | 16 Suppl 2 |
| creator | Goyen, Mathias Shamsi, Kohkan Schoenberg, Stefan O |
| description | Vasovist (MS-325) is the first intravascular contrast agent approved for use with magnetic resonance angiography in the European Union. Vasovist reversibly binds to albumin, providing extended intravascular enhancement compared to existing extracellular magnetic resonance contrast agents. Prior to approval, Vasovist underwent extensive testing to evaluate the safety and efficacy of the drug; the clinical trials program included blinded, placebo-controlled dose ranging, efficacy in a variety of vascular beds (AIOD, renal, pedal), examination of potential drug interaction with warfarin and comparison with XRA. The clinical trials show that Vasovist-enhanced MR angiography is safe and well-tolerated in patients with vascular disease, effective for the detection of vascular stenosis and aneurysms, significantly more accurate (both more sensitive and specific) than non-contrast MR angiography for the diagnosis of vascular stenoses, and similar to conventional angiography for the overall characterization of vascular disease, without the need for catheterization. |
| doi_str_mv | 10.1007/s10406-006-0162-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68572286</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68572286</sourcerecordid><originalsourceid>FETCH-LOGICAL-c299t-3a4a222204dd2e8a19c94829a8d3fd1da1684868599d2fb287edc4a4b4273573</originalsourceid><addsrcrecordid>eNpFkMtKw0AUhgdRbK0-gBvJyt3omUsyc5ZSrAoVQYrb4SQzaSO5mWmFvr0pLXjg52z-C3yM3Qp4EADmMQrQkHE4SGSS4xmbikworkxqztkUUFluEPWEXcX4DQAotLlkE5FZkFrZKUu-KHa_Vdzy0G6oLYJP3j8TatdVtx6o3-yv2UVJdQw3pz9jq8Xzav7Klx8vb_OnJS8k4pYr0iTHA-29DJYEFqitRLJelV54Gie1zWyK6GWZS2uCLzTpXEujUqNm7P5Y2w_dzy7ErWuqWIS6pjZ0u-jGpJHSZqNRHI3F0MU4hNL1Q9XQsHcC3IGKO1JxcNBIxeGYuTuV7_Im-P_ECYP6AyxMWy8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68572286</pqid></control><display><type>article</type><title>Vasovist-enhanced MR angiography</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Goyen, Mathias ; Shamsi, Kohkan ; Schoenberg, Stefan O</creator><creatorcontrib>Goyen, Mathias ; Shamsi, Kohkan ; Schoenberg, Stefan O</creatorcontrib><description>Vasovist (MS-325) is the first intravascular contrast agent approved for use with magnetic resonance angiography in the European Union. Vasovist reversibly binds to albumin, providing extended intravascular enhancement compared to existing extracellular magnetic resonance contrast agents. Prior to approval, Vasovist underwent extensive testing to evaluate the safety and efficacy of the drug; the clinical trials program included blinded, placebo-controlled dose ranging, efficacy in a variety of vascular beds (AIOD, renal, pedal), examination of potential drug interaction with warfarin and comparison with XRA. The clinical trials show that Vasovist-enhanced MR angiography is safe and well-tolerated in patients with vascular disease, effective for the detection of vascular stenosis and aneurysms, significantly more accurate (both more sensitive and specific) than non-contrast MR angiography for the diagnosis of vascular stenoses, and similar to conventional angiography for the overall characterization of vascular disease, without the need for catheterization.</description><identifier>ISSN: 0938-7994</identifier><identifier>ISSN: 1613-3749</identifier><identifier>EISSN: 1613-3757</identifier><identifier>DOI: 10.1007/s10406-006-0162-9</identifier><identifier>PMID: 16802438</identifier><language>eng</language><publisher>Germany</publisher><subject>Contrast Media ; Female ; Gadolinium ; Humans ; Injections, Intravenous ; Magnetic Resonance Angiography - methods ; Male ; Organometallic Compounds ; Radiographic Image Enhancement ; Sensitivity and Specificity ; Vascular Diseases - diagnosis</subject><ispartof>European radiology, 2006-02, Vol.16 Suppl 2 (S2), p.B9-B14</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c299t-3a4a222204dd2e8a19c94829a8d3fd1da1684868599d2fb287edc4a4b4273573</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16802438$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goyen, Mathias</creatorcontrib><creatorcontrib>Shamsi, Kohkan</creatorcontrib><creatorcontrib>Schoenberg, Stefan O</creatorcontrib><title>Vasovist-enhanced MR angiography</title><title>European radiology</title><addtitle>Eur Radiol</addtitle><description>Vasovist (MS-325) is the first intravascular contrast agent approved for use with magnetic resonance angiography in the European Union. Vasovist reversibly binds to albumin, providing extended intravascular enhancement compared to existing extracellular magnetic resonance contrast agents. Prior to approval, Vasovist underwent extensive testing to evaluate the safety and efficacy of the drug; the clinical trials program included blinded, placebo-controlled dose ranging, efficacy in a variety of vascular beds (AIOD, renal, pedal), examination of potential drug interaction with warfarin and comparison with XRA. The clinical trials show that Vasovist-enhanced MR angiography is safe and well-tolerated in patients with vascular disease, effective for the detection of vascular stenosis and aneurysms, significantly more accurate (both more sensitive and specific) than non-contrast MR angiography for the diagnosis of vascular stenoses, and similar to conventional angiography for the overall characterization of vascular disease, without the need for catheterization.</description><subject>Contrast Media</subject><subject>Female</subject><subject>Gadolinium</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Magnetic Resonance Angiography - methods</subject><subject>Male</subject><subject>Organometallic Compounds</subject><subject>Radiographic Image Enhancement</subject><subject>Sensitivity and Specificity</subject><subject>Vascular Diseases - diagnosis</subject><issn>0938-7994</issn><issn>1613-3749</issn><issn>1613-3757</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMtKw0AUhgdRbK0-gBvJyt3omUsyc5ZSrAoVQYrb4SQzaSO5mWmFvr0pLXjg52z-C3yM3Qp4EADmMQrQkHE4SGSS4xmbikworkxqztkUUFluEPWEXcX4DQAotLlkE5FZkFrZKUu-KHa_Vdzy0G6oLYJP3j8TatdVtx6o3-yv2UVJdQw3pz9jq8Xzav7Klx8vb_OnJS8k4pYr0iTHA-29DJYEFqitRLJelV54Gie1zWyK6GWZS2uCLzTpXEujUqNm7P5Y2w_dzy7ErWuqWIS6pjZ0u-jGpJHSZqNRHI3F0MU4hNL1Q9XQsHcC3IGKO1JxcNBIxeGYuTuV7_Im-P_ECYP6AyxMWy8</recordid><startdate>20060201</startdate><enddate>20060201</enddate><creator>Goyen, Mathias</creator><creator>Shamsi, Kohkan</creator><creator>Schoenberg, Stefan O</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060201</creationdate><title>Vasovist-enhanced MR angiography</title><author>Goyen, Mathias ; Shamsi, Kohkan ; Schoenberg, Stefan O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c299t-3a4a222204dd2e8a19c94829a8d3fd1da1684868599d2fb287edc4a4b4273573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Contrast Media</topic><topic>Female</topic><topic>Gadolinium</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Magnetic Resonance Angiography - methods</topic><topic>Male</topic><topic>Organometallic Compounds</topic><topic>Radiographic Image Enhancement</topic><topic>Sensitivity and Specificity</topic><topic>Vascular Diseases - diagnosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goyen, Mathias</creatorcontrib><creatorcontrib>Shamsi, Kohkan</creatorcontrib><creatorcontrib>Schoenberg, Stefan O</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goyen, Mathias</au><au>Shamsi, Kohkan</au><au>Schoenberg, Stefan O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vasovist-enhanced MR angiography</atitle><jtitle>European radiology</jtitle><addtitle>Eur Radiol</addtitle><date>2006-02-01</date><risdate>2006</risdate><volume>16 Suppl 2</volume><issue>S2</issue><spage>B9</spage><epage>B14</epage><pages>B9-B14</pages><issn>0938-7994</issn><issn>1613-3749</issn><eissn>1613-3757</eissn><abstract>Vasovist (MS-325) is the first intravascular contrast agent approved for use with magnetic resonance angiography in the European Union. Vasovist reversibly binds to albumin, providing extended intravascular enhancement compared to existing extracellular magnetic resonance contrast agents. Prior to approval, Vasovist underwent extensive testing to evaluate the safety and efficacy of the drug; the clinical trials program included blinded, placebo-controlled dose ranging, efficacy in a variety of vascular beds (AIOD, renal, pedal), examination of potential drug interaction with warfarin and comparison with XRA. The clinical trials show that Vasovist-enhanced MR angiography is safe and well-tolerated in patients with vascular disease, effective for the detection of vascular stenosis and aneurysms, significantly more accurate (both more sensitive and specific) than non-contrast MR angiography for the diagnosis of vascular stenoses, and similar to conventional angiography for the overall characterization of vascular disease, without the need for catheterization.</abstract><cop>Germany</cop><pmid>16802438</pmid><doi>10.1007/s10406-006-0162-9</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0938-7994 |
| ispartof | European radiology, 2006-02, Vol.16 Suppl 2 (S2), p.B9-B14 |
| issn | 0938-7994 1613-3749 1613-3757 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68572286 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Contrast Media Female Gadolinium Humans Injections, Intravenous Magnetic Resonance Angiography - methods Male Organometallic Compounds Radiographic Image Enhancement Sensitivity and Specificity Vascular Diseases - diagnosis |
| title | Vasovist-enhanced MR angiography |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T19%3A19%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vasovist-enhanced%20MR%20angiography&rft.jtitle=European%20radiology&rft.au=Goyen,%20Mathias&rft.date=2006-02-01&rft.volume=16%20Suppl%202&rft.issue=S2&rft.spage=B9&rft.epage=B14&rft.pages=B9-B14&rft.issn=0938-7994&rft.eissn=1613-3757&rft_id=info:doi/10.1007/s10406-006-0162-9&rft_dat=%3Cproquest_cross%3E68572286%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68572286&rft_id=info:pmid/16802438&rfr_iscdi=true |